Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer.

Wu CC, Wu FC, Hsu YT, Hsiao YC, Yang YC, Chang CA, Chang CL.

Oncotarget. 2017 May 16;8(20):33024-33036. doi: 10.18632/oncotarget.16032.

2.

Native-like Env trimers as a platform for HIV-1 vaccine design.

Sanders RW, Moore JP.

Immunol Rev. 2017 Jan;275(1):161-182. doi: 10.1111/imr.12481. Review.

3.

Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env.

Heydarchi B, Center RJ, Bebbington J, Cuthbertson J, Gonelli C, Khoury G, Mackenzie C, Lichtfuss M, Rawlin G, Muller B, Purcell D.

MAbs. 2017 Apr;9(3):550-566. doi: 10.1080/19420862.2016.1270491. Epub 2016 Dec 20.

4.

Engineering and Characterization of a Fluorescent Native-Like HIV-1 Envelope Glycoprotein Trimer.

Sliepen K, van Montfort T, Ozorowski G, Pritchard LK, Crispin M, Ward AB, Sanders RW.

Biomolecules. 2015 Oct 23;5(4):2919-34. doi: 10.3390/biom5042919.

5.

Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques.

Borggren M, Vinner L, Andresen BS, Grevstad B, Repits J, Melchers M, Elvang TL, Sanders RW, Martinon F, Dereuddre-Bosquet N, Bowles EJ, Stewart-Jones G, Biswas P, Scarlatti G, Jansson M, Heyndrickx L, Grand RL, Fomsgaard A.

Vaccines (Basel). 2013 Jul 19;1(3):305-27. doi: 10.3390/vaccines1030305.

6.

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP.

Science. 2015 Jul 10;349(6244):aac4223. doi: 10.1126/science.aac4223. Epub 2015 Jun 18.

7.

Strategies to guide the antibody affinity maturation process.

Doria-Rose NA, Joyce MG.

Curr Opin Virol. 2015 Apr;11:137-47. doi: 10.1016/j.coviro.2015.04.002. Epub 2015 Apr 24. Review.

8.

Immunosilencing a highly immunogenic protein trimerization domain.

Sliepen K, van Montfort T, Melchers M, Isik G, Sanders RW.

J Biol Chem. 2015 Mar 20;290(12):7436-42. doi: 10.1074/jbc.M114.620534. Epub 2015 Jan 29.

9.

DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Gupta S, Clark ES, Termini JM, Boucher J, Kanagavelu S, LeBranche CC, Abraham S, Montefiori DC, Khan WN, Stone GW.

J Virol. 2015 Apr;89(8):4158-69. doi: 10.1128/JVI.02904-14. Epub 2015 Jan 28.

10.

Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL.

Isik G, Sliepen K, van Montfort T, Sanders RW.

PLoS One. 2014 Sep 23;9(9):e107683. doi: 10.1371/journal.pone.0107683. eCollection 2014.

11.

Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease.

Yu X, Li Z, Zhou Z, Kilby JM, Jiang W.

Epidemiology (Sunnyvale). 2013 Feb 2;3:120.

12.

Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Isik G, van Montfort T, Chung NP, Moore JP, Sanders RW.

J Immunol. 2014 May 15;192(10):4628-35. doi: 10.4049/jimmunol.1303401. Epub 2014 Apr 11.

13.

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection.

Derdeyn CA, Moore PL, Morris L.

Curr Opin HIV AIDS. 2014 May;9(3):210-6. doi: 10.1097/COH.0000000000000057. Review.

14.

HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.

Kanagavelu S, Termini JM, Gupta S, Raffa FN, Fuller KA, Rivas Y, Philip S, Kornbluth RS, Stone GW.

PLoS One. 2014 Feb 28;9(2):e90100. doi: 10.1371/journal.pone.0090100. eCollection 2014.

15.

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP.

PLoS Pathog. 2013 Sep;9(9):e1003618. doi: 10.1371/journal.ppat.1003618. Epub 2013 Sep 19.

16.

Tribody: robust self-assembled trimeric targeting ligands with high stability and significantly improved target-binding strength.

Kim D, Kim SK, Valencia CA, Liu R.

Biochemistry. 2013 Oct 15;52(41):7283-94. doi: 10.1021/bi400716w. Epub 2013 Oct 3.

17.

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Bontjer I, Melchers M, Tong T, van Montfort T, Eggink D, Montefiori D, Olson WC, Moore JP, Binley JM, Berkhout B, Sanders RW.

PLoS One. 2013 Jun 26;8(6):e67484. doi: 10.1371/journal.pone.0067484. Print 2013.

18.

An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells.

Isik G, Chung NP, van Montfort T, Menis S, Matthews K, Schief WR, Moore JP, Sanders RW.

PLoS One. 2013 Jun 24;8(6):e67309. doi: 10.1371/journal.pone.0067309. Print 2013.

19.

Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.

Ma Y, Xiang D, Sun J, Ding C, Liu M, Hu X, Li G, Kloecker G, Zhang HG, Yan J.

J Immunol. 2013 Jun 1;190(11):5588-99. doi: 10.4049/jimmunol.1203216. Epub 2013 Apr 29. Erratum in: J Immunol. 2016 May 1;196(9):3969.

20.

Chimeric HIV-1 envelope glycoproteins with potent intrinsic granulocyte-macrophage colony-stimulating factor (GM-CSF) activity.

Isik G, van Montfort T, Boot M, Cobos Jiménez V, Kootstra NA, Sanders RW.

PLoS One. 2013;8(4):e60126. doi: 10.1371/journal.pone.0060126. Epub 2013 Apr 2.

Supplemental Content

Support Center